Literature DB >> 10321812

Clinical experience of sex determination by fluorescent in-situ hybridization for preimplantation genetic diagnosis.

C Staessen1, E Van Assche, H Joris, M Bonduelle, M Vandervorst, I Liebaers, A Van Steirteghem.   

Abstract

In our centre we started using fluorescent in-situ hybridization (FISH) technique for sexing in couples with sex-linked diseases in May 1995. Probes specific for chromosomes X, Y and 18 were applied, allowing us to detect simultaneously both gender and ploidy status. The efficiency of the FISH procedure is 90.4% per biopsied blastomere or 95.2% per biopsied blastomere with a distinct nucleus visible at spreading. Up to December 1997, we treated 15 couples (20 treatment cycles) at risk for X-linked recessive disease and two couples with Yq deletion (two treatment cycles) with the aim of transferring only female embryos. In one cycle, no embryos suitable for biopsy were obtained and in five cycles no normal female embryos were available at diagnosis. In the remaining 16 cycles, transfer was possible and six pregnancies ensued: one miscarriage has occurred and six children have been born from the other five pregnancies. The implantation rate (fetal sacs) per transferred embryo was 20.8%. In 98 (61%) of the 161 diagnosed embryos, a diploid status was observed in one or in both biopsied blastomeres. In 10 out of the 161 (6.2%) embryos a heterogeneity among the two biopsied blastomeres was found: a diploid nucleus in one blastomere and a non-diploid pattern or binuclear status in the other. In the remaining 53 (32.9%) out of 161 diagnosed embryos, the biopsied blastomeres were abnormal. The embryos that were not transferred or frozen were further analysed. When two sex chromosomes and two autosomes were present in the biopsied blastomere, the sex determination of the biopsied blastomere was never in conflict with the sex determination in the rest of the embryo. Furthermore, if the biopsied cell was diagnosed as abnormal (triploid, aneuploid, chaotic) the embryo was indeed completely abnormal or at least mosaic. A FISH error could not be excluded in two embryos (1.2%); however, a wrong gender determination did not result from this.

Entities:  

Mesh:

Year:  1999        PMID: 10321812     DOI: 10.1093/molehr/5.4.382

Source DB:  PubMed          Journal:  Mol Hum Reprod        ISSN: 1360-9947            Impact factor:   4.025


  6 in total

Review 1.  Regulating preimplantation genetic diagnosis--how to control PGD.

Authors:  Naoki Takeshita; Harumi Kubo
Journal:  J Assist Reprod Genet       Date:  2004-01       Impact factor: 3.412

2.  Detection of embryo sex chromosome by dual color fluorescent in-situ hybridization.

Authors:  Qun Liu; Guijin Zhu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2003

3.  Higher degree of chromosome mosaicism in preimplantation embryos from carriers of robertsonian translocation t(13;14) in comparison with embryos from karyotypically normal IVF patients.

Authors:  Serena Emiliani; Eric Gonzalez-Merino; Marc Van den Bergh; Marc Abramowicz; Yvon Englert
Journal:  J Assist Reprod Genet       Date:  2003-02       Impact factor: 3.412

4.  Different probe combinations for assessment of postzygotic chromosomal imbalances in human embryos.

Authors:  Magdalena Bielanska; Seang Lin Tan; Asangla Ao
Journal:  J Assist Reprod Genet       Date:  2002-04       Impact factor: 3.412

5.  A decade of molecular preimplantation genetic diagnosis of 350 blastomeres for beta-thalassemia combined with HLA typing, aneuploidy screening and sex selection in Iran.

Authors:  Marzieh Mojbafan; Sirous Zeinali; Yeganeh Keshvar; Solmaz Sabeghi; Zohreh Sharifi; Kiyana Sadat Fatemi; Panti Fouladi; Shahrzad Younesi Khah; Faezeh Rahiminejad; Atefeh Joudaki; Masoume Amini; Hamideh Bagherian; Marefat Ghaffari Novin; Mansoureh Movahedin
Journal:  BMC Pregnancy Childbirth       Date:  2022-04-15       Impact factor: 3.007

6.  Preimplantation genetic diagnosis: design or too much design.

Authors:  W Verpoest
Journal:  Facts Views Vis Obgyn       Date:  2009
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.